Earnings call transcript: Cloetta surges on strong Q2 2026 margin gains

Cloetta reported Q2 organic growth of 3.3% and adjusted operating margin of 14.9%, alongside record-low leverage with net debt/EBITDA at 0.8x (net debt SEK 1.2B), lifting shares 11.15% to $53.95 pre-market. Management guided to a 12% full-year operating margin for 2026 despite expected second-half margin dilution from higher marketing and U.S./Germany expansion costs. Free cash flow increased to SEK 86M in Q2 (SEK 230M in H1), and the company paid a dividend of SEK 401M in Q2 (+27% YoY, SEK 140/share).

Analysis

The market is treating this as a quality rerating, but the more important mechanism is that Cloetta has proved its cost base is now structurally lower while its brands can still grow without heavy discounting. That combination supports a higher multiple than a typical Nordic staples name, especially with leverage at a point where dividend policy and buybacks become more flexible. The immediate risk is that investors extrapolate a peak quarter into a permanent margin step-up; management is explicitly signaling the opposite, so some of today’s gap may fade once the market prices in H2 spend.

Second-order, the bigger winner is not just Cloetta’s earnings power but its bargaining position with retailers in Sweden, the Netherlands, and eventually Germany/U.S. A cleaner balance sheet and more cash flow let the company spend on shelf space, marketing, and launch support without stressing the P&L, which can squeeze smaller confectionery players and private-label incumbents that lack that firepower. The U.S. and Germany initiatives are still option value, but if even modestly successful they can shift the story from mature cash cow to low-capex geographic compounding.

Contrarian view: the consensus may be underestimating how much of the valuation case is already in the stock after the pre-market jump, while overestimating near-term growth from expansion. What matters over the next 1-3 months is not the headline margin print but whether Q3 shows any erosion in organic volume once marketing normalizes and commodity hedges roll. Over 6-18 months, the thesis breaks if margin reverts below ~12% on a full-year basis or if the U.S. rollout requires local sourcing, which would raise complexity and dilute the current margin story.

Key Decisions for Investors

• Do not chase the gap: wait for a 5-8% pullback in CLOEF/CLOE.ST before adding; the stock is now near resistance and the easy re-rating may already be captured.
• Tactical long CLOEF/CLOE.ST versus MDLZ over the next 1-3 months: the trade is on superior operating leverage and balance-sheet optionality, but only if Q3 commentary confirms H2 margins stay above ~11-12%.
• Take partial profits into strength if CLOEF trades above the 52-week high and management does not raise the full-year margin outlook; the catalyst path is slower than the initial move implies.
• Set a watch item for Q3 gross margin and A&P spend: if marketing/expansion costs rise without a corresponding acceleration in organic volume, fade the move and consider reducing exposure.